Fig. 4 | Scientific Reports

Fig. 4

From: Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib

Fig. 4

Overall survival of patients treated with lenvatinib (LEN). (a) Median overall survival (OS) for mALBI grade 1, 2a, 2b, and 3 was 28.61 (95% CI 23.86–35.36), 20.0 (95% CI 15.21–24.32), 12.39 (95% CI 9.82–15.11), and 4.68 (95% CI 0.26–11.54) months, respectively (p < 0.001). (b) Median OS for NLR < 4 was 22.11 (95% CI 18.64–27.21) and for NLR ≥ 4 was 10.46 (95% CI 8.39–13.64) months (p < 0.001). (c) Median OS for O-PNI < 40 was 9.61 (95% CI 8.39–11.86) and for O-PNI ≥ 40 was 27.21 (95% CI 22.46–30.86) months (p < 0.001). (d) Median OS neo-GPS 0, 1, and 2 was 22.89 (95% CI 18.36–27.57), 12.68 (95% CI 9.82–18.14), and 11.0 (95% CI 4.46–not applicable) months, respectively (p < 0.001).

Back to article page